If current inhibition with ivabradine: further perspectives
Hôpital Européen Georges Pompidou, Paris, France
* Nicolas Danchin, Hôpital Européen Georges Pompidou, 20 rue Leblanc, 75015 Paris, France.
Abstract
Beyond its antianginal properties, the specific If (pacemaker, or ‘funny’, current) channel blocker ivabradine has many possible clinical uses. The first potential application of ivabradine results from its ability to decrease myocardial ischaemia. Because myocardial ischaemia has a definite impact on outcome, its reduction is likely to improve prognosis in patients with coronary artery disease (CAD). In such patients, lowering the heart rate per se might also reduce risk for sudden cardiac death or acute coronary events, as a strong link exists between heart rate and plaque rupture, which is the triggering mechanism of most complications of CAD. Most importantly, If current inhibition might be useful in patients with congestive heart failure. In such patients, there is a parallel between heart rate reduction and the beneficial clinical effects achieved with beta-blockers. Observational studies, on the other hand, show that only a minority of patients with heart failure receive beta-blockers; If current inhibition might constitute an alternative in such patients. Diastolic heart failure remains a therapeutic challenge, and prolonging the diastolic time is likely to prove beneficial. Because ivabradine has no negative impact on left ventricular function, it might also be useful for controlling heart rate in patients with acute heart failure treated with agents such as dobutamine. Future studies will determine whether ivabradine fulfils part, or all, of this promise.
Key Words: If current inhibition • Ivabradine • Coronary artery disease • Congestive heart failure
References
- Dyer AR, Persky V, Stamler J, et al. Heart rate as a prognostic factor for coronary heart disease and mortality: findings in three Chicago epidemiologic studies. Am J Epidemiol. 1980;112:736–749
[Abstract/Free Full Text] - Hjalmarson A, Gilpin EA, Kjekshus J, et al. Influence of heart rate on mortality after myocardial infarction. Am J Cardiol. 1990;65:547–553[CrossRef][Web of Science][Medline]
- Aronow WS, Ahn C, Mercando AD, Epstein S. Association of average heart rate on 24-hour ambulatory electrocardiograms with incidence of new coronary events at 48-month follow-up in 1,311 patients (mean age 81 years) with heart disease and sinus rhythm. Am J Cardiol. 1996;78:1175–1176[Web of Science][Medline]
- Beere PA, Glagov S, Zarins CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science. 1984;226:180–182
[Abstract/Free Full Text] - Kaplan JR, Manuck SB, Clarkson TB. The influence of heart rate on coronary atherosclerosis. J Cardiovasc Pharmacol. 1987;10(suppl 2):S100–S102
- Marie PY, Danchin N, Branly F, et al. Effects of medical therapy on outcome assessment using exercise thallium-201 single photon emission computed tomography imaging. Evidence of a protective effect of beta-blocking antianginal medications. J Am Coll Cardiol. 1999;34:113–121
[Abstract/Free Full Text] - Fox KM, Mulcahy D, Findlay I, Ford I, Dargie HJ. The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination of the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group. Eur Heart J. 1996;17:96–103
[Abstract/Free Full Text] - Freemantle N, Cleland J, Young P, Mason J, Harrison J. Beta-blockade after myocardial infarction: systematic review and meta-regression analysis. BMJ. 1999;318:1730–1737
[Abstract/Free Full Text] - Heidland UE, Strauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation. 2001;104:1477–1482
[Abstract/Free Full Text] - Lechat P, Packer M, Chalon S, et al. Clinical effects of ß-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomised trials. Circulation. 1998;98:1184–1191
[Abstract/Free Full Text] - MERIT-HF study group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:9–13[CrossRef][Web of Science][Medline]
- Nagatsu M, Spinale FG, Koide M, et al. Bradycardia and the role of ß-blockade in the amelioration of left ventricular dysfunction. Circulation. 2000;101:653–659
[Abstract/Free Full Text] - Singh BN. Morbidity and mortality in cardiovascular disorders: impact of reduced heart rate. J Cardiovasc Pharmacol Therapeut. 2001;6:313–331
[Free Full Text] - Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II trial. Circulation. 2001;103:1428–1433
[Abstract/Free Full Text] - Mulder P, Barbier S, Richard V, et al. Long-term heart rate reduction induced by the If current inhibitor ivabradine improves cardiac function and structure in rats with heart failure. [abstract]Eur Heart J. 2002;23:370 (abstract suppl)
- Remme WJ, Swedberg K. Task Force for the diagnosis and treatment of chronic heart failure, European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J. 2001;22:1527–1560
[Free Full Text] - Andersson B, Caidhal K, di Lenarda A, et al. Changes in early and late diastolic filling patterns induced by long-term adrenergic ß-blockade in patients with idiopathic dilated cardiomyopathy. Circulation. 1996;94:673–682
[Abstract/Free Full Text] - Colin P, Ghaleh B, Hittinger L, et al. Differential effects of heart rate reduction and ß-blockade on left ventricular relaxation during exercise. Am J Physiol Heart Circ Physiol. 2002;282:H672–H679
[Abstract/Free Full Text]
CiteULike 
Connotea 
Del.icio.us What's this?
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||